TORONTO, April 27, 2017 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company", TSE ticker PMN.TO), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it will present results on its recent Alzheimer's disease (AD) therapeutic developments on Friday, April 28th at the 2017 annual meeting of the American Academy of Neurology (AAN), held in Boston, MA, from April 22-28.
"Based on our results presented at this year's AAN annual meeting we anticipate ProMIS monoclonal antibodies (mAbs), selectively targeting toxic forms of Amyloid beta (Aβ), will demonstrate a 'best in class' product profile for treatment of AD," stated Dr. Elliot Goldstein, ProMIS President and CEO. "Indeed, by virtually no binding to Aβ monomer, ProMIS mAb products should allow improved efficacy by avoiding targeting of this abundant, non-toxic form of Aβ. Similarly, by not targeting plaque which is associated with neurovascular edema ('brain swelling'), a dose limiting adverse event, we anticipate improved safety and tolerability for our products".
The presentation, entitled Achieving the optimal profile for Alzheimer's immunotherapy: Rational generation of antibodies specific for toxic Aβ oligomers is a poster authored by Dr. Steven Plotkin (et al.), the Company's Chief Physics Officer and presented by Dr. Johanne Kaplan, ProMIS Chief Development Officer. Using one of the Company's unique, proprietary discovery platforms, Collective Coordinates, the authors predicted five distinct epitopes (targets) on toxic pathogenic Aβ oligomers (prion-like forms of Aβ). Results of the predictive methodology indicate that these oligomer-specific epitopes are conformationally distinct, in other words shaped differently from the same primary sequences in either Aβ monomer or fibrils, the latter representing the main constituent of Aβ plaque. The authors conclude that monoclonal antibodies generated by immunizing with the predicted conformational epitopes bind selectively to toxic Aβ oligomers, inhibit Aβ propagation (spreading) in vitro, bind preferentially to AD brain tissue and cerebrospinal fluid (CSF), show little or no reactivity to plaques in cadaveric AD brain and protect against Aβ toxicity in vitro. Furthermore, the Company's lead product, PMN310, was shown to preserve cognitive function in a preclinical animal model evaluating short term memory retention (dual object recognition test).
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.
The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at: www.promisneurosciences.com
SOURCE ProMIS Neurosciences Inc.